Boston Scientific Corp (BSX)vsCME Group Inc (CME)
BSX
Boston Scientific Corp
$69.78
+2.39%
HEALTHCARE · Cap: $101.28B
CME
CME Group Inc
$293.93
-2.89%
FINANCIAL SERVICES · Cap: $105.67B
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 209% more annual revenue ($20.07B vs $6.51B). CME leads profitability with a 62.6% profit margin vs 14.4%. BSX appears more attractively valued with a PEG of 0.75. CME earns a higher WallStSmart Score of 63/100 (C+).
BSX
Buy63
out of 100
Grade: C+
CME
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+1.2%
Fair Value
$70.62
Current Price
$69.78
$0.84 discount
Margin of Safety
+43.8%
Fair Value
$522.76
Current Price
$293.93
$228.83 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Growing faster than its price suggests
15.9% revenue growth
Generating 1.0B in free cash flow
Keeps 63 of every $100 in revenue as profit
Strong operational efficiency at 63.8%
Large-cap with strong market position
Conservative balance sheet, low leverage
Earnings expanding 35.0% YoY
Generating 1.1B in free cash flow
Areas to Watch
Premium valuation, high expectations priced in
Moderate valuation
Weak financial health signals
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.
Bull Case : CME
The strongest argument for CME centers on Profit Margin, Operating Margin, Market Cap. Profitability is solid with margins at 62.6% and operating margin at 63.8%.
Bear Case : BSX
The primary concerns for BSX are P/E Ratio.
Bear Case : CME
The primary concerns for CME are P/E Ratio, Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
BSX profiles as a growth stock while CME is a mature play — different risk/reward profiles.
BSX carries more volatility with a beta of 0.70 — expect wider price swings.
BSX is growing revenue faster at 15.9% — sustainability is the question.
CME generates stronger free cash flow (1.1B), providing more financial flexibility.
Bottom Line
BSX scores higher overall (63/100 vs 63/100) and 15.9% revenue growth. CME offers better value entry with a 43.8% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
CME Group Inc
FINANCIAL SERVICES · FINANCIAL DATA & STOCK EXCHANGES · USA
CME Group Inc. (Chicago Mercantile Exchange, Chicago Board of Trade, New York Mercantile Exchange, The Commodity Exchange) is an American global markets company. It is the world's largest financial derivatives exchange, and trades in asset classes that include agricultural products, currencies, energy, interest rates, metals, stock indexes and cryptocurrencies futures.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?